Your browser doesn't support javascript.
loading
Positive feedback loop PU.1-IL9 in Th9 promotes rheumatoid arthritis development.
Tu, Jiajie; Chen, Weile; Huang, Wei; Wang, Xinming; Fang, Yilong; Wu, Xuming; Zhang, Huiru; Liu, Chong; Tan, Xuewen; Zhu, Xiangling; Wang, Huihui; Han, Dafei; Chen, Yizhao; Wang, Anqi; Zhou, Yuanyuan; Xue, Zimeng; Xue, Hui; Yan, Shangxue; Zhang, Lingling; Li, Zhenbao; Yang, Chunlan; Deng, Yujie; Zhang, Shihao; Zhu, Chen; Wei, Wei.
Affiliation
  • Tu J; Institute of Clinical Pharmacology, Anhui Medical University, Hefei, Anhui, China.
  • Chen W; Institute of Clinical Pharmacology, Anhui Medical University, Hefei, Anhui, China.
  • Huang W; Department of Orthopedics, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
  • Wang X; Department of Pharmacy, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
  • Fang Y; Institute of Clinical Pharmacology, Anhui Medical University, Hefei, Anhui, China.
  • Wu X; Institute of Clinical Pharmacology, Anhui Medical University, Hefei, Anhui, China.
  • Zhang H; Institute of Clinical Pharmacology, Anhui Medical University, Hefei, Anhui, China.
  • Liu C; Institute of Clinical Pharmacology, Anhui Medical University, Hefei, Anhui, China.
  • Tan X; Institute of Clinical Pharmacology, Anhui Medical University, Hefei, Anhui, China.
  • Zhu X; Institute of Clinical Pharmacology, Anhui Medical University, Hefei, Anhui, China.
  • Wang H; Institute of Clinical Pharmacology, Anhui Medical University, Hefei, Anhui, China.
  • Han D; Institute of Clinical Pharmacology, Anhui Medical University, Hefei, Anhui, China.
  • Chen Y; Institute of Clinical Pharmacology, Anhui Medical University, Hefei, Anhui, China.
  • Wang A; Institute of Clinical Pharmacology, Anhui Medical University, Hefei, Anhui, China.
  • Zhou Y; Institute of Clinical Pharmacology, Anhui Medical University, Hefei, Anhui, China.
  • Xue Z; Institute of Clinical Pharmacology, Anhui Medical University, Hefei, Anhui, China.
  • Xue H; Institute of Clinical Pharmacology, Anhui Medical University, Hefei, Anhui, China.
  • Yan S; Institute of Clinical Pharmacology, Anhui Medical University, Hefei, Anhui, China.
  • Zhang L; Institute of Clinical Pharmacology, Anhui Medical University, Hefei, Anhui, China.
  • Li Z; College of Pharmacy, Anhui University of Traditional Chinese Medicine, Hefei, Anhui, China.
  • Yang C; Department of Pharmacy, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
  • Deng Y; Guangzhou National Laboratory, Guangzhou, China.
  • Zhang S; Institute of Clinical Pharmacology, Anhui Medical University, Hefei, Anhui, China wwei@ahmu.edu.cn zhuchena@ustc.edu.cn shihaozhang@ahmu.edu.cn.
  • Zhu C; Department of Orthopedics, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China wwei@ahmu.edu.cn zhuchena@ustc.edu.cn shihaozhang@ahmu.edu.cn.
  • Wei W; Institute of Clinical Pharmacology, Anhui Medical University, Hefei, Anhui, China wwei@ahmu.edu.cn zhuchena@ustc.edu.cn shihaozhang@ahmu.edu.cn.
Ann Rheum Dis ; 2024 Aug 20.
Article in En | MEDLINE | ID: mdl-39164066
ABSTRACT

OBJECTIVES:

T helper 9 (Th9) cells are recognised for their characteristic expression of the transcription factor PU.1 and production of interleukin-9 (IL-9), which has been implicated in various autoimmune diseases. However, its precise relationship with rheumatoid arthritis (RA) pathogenesis needs to be further clarified.

METHODS:

The expression levels of PU.1 and IL-9 in patients with RA were determined by ELISA, western blotting (WB) and immunohistochemical staining. PU.1-T cell-conditional knockout (KO) mice, IL-9 KO and IL-9R KO mice were used to establish collagen antibody-induced arthritis (CAIA), respectively. The inhibitor of PU.1 and IL-9 blocking antibody was used in collagen-induced arthritis (CIA). In an in vitro study, the effects of IL-9 were investigated using siRNAs and IL-9 recombinant proteins. Finally, the underlying mechanisms were further investigated by luciferase reporter analysis, WB and Chip-qPCR.

RESULTS:

The upregulation of IL-9 expression in patients with RA exhibited a positive correlation with clinical markers. Using CAIA and CIA model, we demonstrated that interventions targeting PU.1 and IL-9 substantially mitigated the inflammatory phenotype. Furthermore, in vitro assays provided the proinflammatory role of IL-9, particularly in the hyperactivation of macrophages and fibroblast-like synoviocytes. Mechanistically, we uncovered that PU.1 and IL-9 form a positive feedback loop in RA (1) PU.1 directly binds to the IL-9 promoter, activating its transcription and (2) Th9-derived IL-9 induces PU.1 via the IL-9R-JAK1/STAT3 pathway.

CONCLUSIONS:

These results support that the PU.1-IL-9 axis forms a positive loop in Th9 dysregulation of RA. Targeting this signalling axis presents a potential target approach for treating RA.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Ann Rheum Dis Year: 2024 Document type: Article Affiliation country: China Country of publication: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Ann Rheum Dis Year: 2024 Document type: Article Affiliation country: China Country of publication: United kingdom